Exeter Analytical Launches New Website
Exeter Analytical has launched a new website to provide visitors with in-depth information relating to the company's performance leading range of elemental (CHN) analysers, top quality microanalysis consumables and analytical services provided by subsidiary company — Warwick Analytical Service (WAS).
Designed to enable visitors to effortlessly navigate through Exeter Analytical products, the portfolio of ISO 17025 accredited analytical services from WAS and growing applications note bibliography, the new site at www.exeter-analytical.co.uk/ is a site worth bookmarking. Reflecting rapidly growing use of Exeter Analytical CHN analysers in environmental applications a series of new pages have been added describing the considerable benefits of the technique including soil and sediment analysis, waste material fuel value determination and filter analysis of air and water samples.
Exeter Analytical manufacture and sell the Model 440 CHN Elemental Analyser, which is based on a unique horizontal furnace design. In many independent evaluations the system has been shown the most accurate and precise available on the market today, capable of performing the widest range of sample applications.
In addition to the manufacturing of analytical instrumentation Exeter Analytical also maintains an analytical facility through subsidiary — Warwick Analytical service that specializes in providing elemental analysis (metals, CHN, Halogen determination etc.) as an analytical service. This enables Exeter analytical to offer unsurpassed application support as well as a free CHN analysis service to all its customers. During the last 25+ years, Exeter Analytical has built-up extensive knowledge across a broad cross section of elemental analysis applications and are always happy to offer free applications advice. Exeter Analytical holds full ISO 9001 and ISO 17025 accreditation and can provide analytical service work that is GMP compliant.
For further information please visit www.exeteranalytical.co.uk or contact Exeter Analytical on tel. +44 (0)2476 323 223 or email [email protected]
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
.png)
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance